Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method

European Respiratory Journal

Volumn 48, Issue 4, 2016, Pages 1160-1170

  Mitnick, Carole D ^a,b   White, Richard A ^c   Lu, Chunling ^a,d   Rodriguez, Carly A ^a   Bayona, Jaime ^e   Becerra, Mercedes C ^a,b,d   Burgos, Marcos ^f   Centis, Rosella ^g   Cohen, Theodore ^h   Cox, Helen ⁱ   D'Ambrosio, Lia ^g,j   Danilovitz, Manfred ^k   Falzon, Dennis ^l   Gelmanova, Irina Y ^b   Gler, Maria T ^m   Grinsdale, Jennifer A ⁿ   Holtz, Timothy H ^o   Keshavjee, Salmaan ^a,b,d   Leimane, Vaira ^p   Menzies, Dick ^q   Migliori, Giovanni Battista ^g   Milstein, Meredith B ^a,r   Mishustin, Sergey P ^s   Pagano, Marcello ^t   Quelapio, Maria I ^u   Shean, Karen ^v   Shin, Sonya S ^a,b,d,e   Tolman, Arielle W ^a   Van Der Walt, Martha L ^w   Van Deun, Armand ^x   Viiklepp, Piret ^y   Ahuja, Shama D ^z   Andreev, Yevgeny G ^aa   Ashkin, David ^ab   Avendano, Monika ^ac   Banerjee, Rita ^ad   Bauer, Melissa ^q   Benedetti, Andrea ^q   Brand, Jeannette ^w   Chan, Edward D ^ae   Chiang, Chen Yuan ^af   DeRiemer, Kathy ^af   Dung, Nguyen Huy ^ag   Enarson, Donald ^ah   Flanagan, Katherine ^ai   Flood, Jennifer ^aj   García García, Lourdes ^ak   Gandhi, Neel ^o   Granich, Reuben M ^o   Hollm Delgado, Maria G ^q   Iseman, Michael D ^am   Jarlsberg, Leah G ^am   Kim, Hye Ryoun ^an   Koh, Won Jung ^ao   Lancaster, Joey ^w   Lange, Christophe ^ap   De Lange, Wiel C M ^aq   Leung, Chi Chiu ^ar   Li, Jiehui ^as   Maug, Aung Kya Jai ^at   Narita, Masa ^au   Odendaal, Ronel ^w   O'Riordan, Philly ^av   Pai, Madhukar ^q   Palmero, Domingo ^aw   Seung Kyu, ^ax   Pasvol, Geoffrey ^ay   Peña, Jose ^az   Pérez Guzmán, Carlos ^ba   Ponce De Leon, Alfredo ^bb   Riekstina, Vija ^bc   Robert, Jerome ^bd   Royce, Sarah ^am   Schaaf, H Simon ^be   Seung, Kwonjune J ^d   Shah, Lena ^q   Shim, Tae Sun ^bf   Shiraishi, Yuji ^bg   Sifuentes Osornio, José ^bb   Strand, Matthew J ^al,am   Shaheed, Payam Tabarsi ^bh   Tupasi, Thelma E ^u   Van Altena, Robert ^aq   Van Der Werf, Tjip S ^aq   Vargas, Mario H ^bi   Westenhouse, Janice ^bj   Yew, Wing Wai ^bk   Yim, Jae Joon ^bl   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e SOCIOS EN SALUD   (Peru)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g IRCCS   (Italy)

^h YALE UNIVERSITY   (United States)

ⁱ MÉDECINS SANS FRONTIÈRES   (Switzerland)

^j Public Health Consulting Group SAGL   (Switzerland)

^k TARTU UNIVERSITY HOSPITAL   (Estonia)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m MAKATI MEDICAL CENTER   (Philippines)

ⁿ SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^o CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^p State Agency of Tuberculosis and Lung Diseases   (Latvia)

^q MCGILL UNIVERSITY   (Canada)

^r NORTHEASTERN UNIVERSITY   (United States)

^s Tomsk TB and Pulmonary Medical Center   (Russian Federation)

^t HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^u Tropical Disease Foundation Inc   (Philippines)

^v UNIVERSITY OF CAPE TOWN   (South Africa)

^w SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^x INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^y National Institute for Heath Development   (Estonia)

^z Bureau of Tuberculosis   (United States)

^aa Ministry of Justice   (Russian Federation)

^ab AG Holley Hospital   (United States)

^ac UNIVERSITY OF TORONTO   (Canada)

^ad MAYO CLINIC   (United States)

^ae Veterans Affairs Eastern Colorado Health Care System   (United States)

^af UNIVERSITY OF CALIFORNIA   (United States)

^ag National TB Programme   (Viet Nam)

^ah INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^ai MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^aj CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^ak INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^al DEPARTMENT OF MEDICINE   (United States)

^am UNIVERSITY OF CALIFORNIA   (United States)

^an Korea Cancer Center Hospital   (South Korea)

^ao Samsung Medical Center   (South Korea)

^ap Tuberculosis Center Borstel   (Germany)

^aq UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ar DEPARTMENT OF HEALTH   (Hong Kong)

^as New York City Health and Mental Hygiene   (United States)

^at Damien Foundation   (Bangladesh)

^au UNIVERSITY OF WASHINGTON   (United States)

^av Medical Centre   (United Kingdom)

^aw HOSPITAL F J MUÑIZ   (Argentina)

^ax TB Center   (South Korea)

^ay IMPERIAL COLLEGE LONDON   (United Kingdom)

^az UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^ba Instituto de Salud del Estado de Aguascalientes (ISEA)   (Mexico)

^bb Laboratorio de Microbiología   (Mexico)

^bc Clinic of Tuberculosis and Lung Diseases   (Latvia)

^bd SORBONNE UNIVERSITÉ   (France)

^be STELLENBOSCH UNIVERSITY   (South Africa)

^bf University of Ulsan College of Medicine   (South Korea)

^bg Japan Anti Tuberculosis Association   (Japan)

^bh SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^bi INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^bj Center for Infectious Diseases California Department of Public Health   (United States)

^bk GRANTHAM HOSPITAL   (Hong Kong)

^bl Seoul National University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SENSITIVITY; FAILURE DETECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAPID TEST; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT FAILURE; DRUG EFFECT; KAPLAN MEIER METHOD; LUNG TUBERCULOSIS; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODEL; RISK; SPUTUM;

TUBERCULOSTATIC AGENT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; COINFECTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODELS; RISK; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84990051246     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00462-2016     Document Type: Article

References (41)

1. World Health Organization. Global Tuberculosis Report 2014. Geneva, World Health Organization, 2014. WHO/ HTM/TB/2014.08.
2. Keshavjee S, Farmer PE. Picking up the pace - scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010; 363: 1781-1784.
3. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: Emergency Update 2008. Geneva, World Health Organization, 2008.
4. Wang M, Guan X, Chi Y, et al. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): a systematic review of randomised clinical trials. Tuberculosis 2015; 95: 364-372.
5. Gammino VM, Taylor AB, Rich ML, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
6. Lu C, Liu Q, Sarma A, et al. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One 2013; 8: e56074.
7. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 387-394.
8. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
9. Kurbatova EV, Gammino VM, Bayona J, et al. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis 2011; 15: 1553-1555.
10. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: 2011 Update. Geneva, World Health Organization, 2011.
11. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
12. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012; 9: e1001300.
13. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
14. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374.
15. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
16. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS One 2009; 4: e6914.
17. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
18. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
19. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
20. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975.
21. Cox H, Kebede Y, Allamuratova S, et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 2006; 3: e384.
22. Holtz TH, Lancaster J, Laserson KF, et al. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655.
23. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
24. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
25. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3: 288-296.
26. Hargreaves NJ, Kadzakumanja O, Whitty CJ, et al. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis 2001; 5: 847-854.
27. Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis and treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011; 134: 850-865.
28. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50: Suppl. 3, S223-SS30.
29. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196: Suppl. 1, S86-107.
30. Rajeswari R, Balasubramanian R, Muniyandi M, et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis 1999; 3: 869-877.
31. Kamolratanakul P, Sawert H, Kongsin S, et al. Economic impact of tuberculosis at the household level. Int J Tuberc Lung Dis 1999; 3: 596-602.
32. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
33. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
34. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
35. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
36. Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014; 43: 1763-1775.
37. Dara M, Sotgiu G, Zaleskis R, et al. Untreatable tuberculosis: is surgery the answer? Eur Respir J 2015; 45: 577-582.
38. Luthuli BB, Purdy GE, Balagaddé FK. Confinement-induced drug-tolerance in mycobacteria mediated by an efflux mechanism. PLoS One 2015; 10: e0136231.
39. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
40. Chiang CY, Van Deun A, Trébucq A, et al. Treatment of multidrug-resistant tuberculosis: definition of the outcome 'failure'. Int J Tuberc Lung Dis 2011; 15: 4-5.
41. Hanna BA, Ebrahimzadeh A, Elliott LB. Multicenter evaluation of the BACTEC MGIT 960 System for recovery of mycobacteria. J Clin Microbiol 1999; 37: 748-752.